FDA advisers recommend approving weight loss drug
(AP) -- Advisers to government health regulators on Thursday recommended that that they approve sales of what would be the first new prescription weight-loss drug in the U.S. in more than a decade, despite concerns over cardiac risks.
A panel of expert advisers to the Food and Drug Administration voted 18-4 to recommend approval of lorcaserin, developed by Arena Pharmaceuticals Inc. They concluded that its benefits "outweigh the potential risks when used long term" in overweight and obese people. One panel member abstained from voting.
Lorcaserin is one of three experimental weight-loss drugs whose developers have been trying for a second time to win approval, after the FDA shot them all down in 2010 or early 2011 because of serious potential side effects.
The panel's vote Thursday comes two days after federal health regulators gave a surprisingly favorable assessment of lorcaserin, the same diet pill the agency turned down in 2010.
At the time, scientists raised concerns about health issues including tumors that developed in laboratory animals tested with the drug.
In the interim, the San Diego company again applied for approval, submitting additional data in hopes of swaying the agency to a favorable decision.
A review of all the research studies by FDA staff, posted online Tuesday, stated that new analysis Arena submitted suggests there's only a "negligible risk" of tumors in people taking the drug. However, questions remain about it possibly increasing risk of high blood pressure in diabetics or damaging heart valves, a life-threatening side effect that has been an issue with some earlier weight-loss pills.
The FDA is not bound to follow the advice of its advisory panels, but generally does so.
Earlier this year, rival Vivus Inc. won a surprising endorsement from an FDA panel for its diet drug, Qnexa. That move raised expectations for both Arena and Orexigen Therapeutics Inc., the third company racing to get the first new diet drug into drugstores.
But a month ago, Vivus said that the FDA had pushed back its target date for a final decision on Qnexa from April 17 until July 17. The agency said it needed more time to consider a new drug safety plan submitted by Vivus.
While patients and doctors are eager for new options to fight obesity, none of these drugs enable patients to magically shed pounds.
Research showed that study subjects taking lorcaserin had modest weight loss, on average losing just 3.1 percent of starting body weight over a year. More than 37 percent of patients lost 5 percent of their weight or more, which is enough to meet FDA standards for effectiveness. By comparison, average weight loss with Qnexa was 11 percent, with more than 83 percent of patients losing 5 percent of their weight or more.
In trading Thursday before the decision was announced, Arena shares rose 24 cents, or 7 percent, to $3.66. The stock was halted for trade in the after-hours. Shares of Orexigen added 12 percent, or 40 cents, to $3.75 in late trading.
©2012 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
- Vivus weight loss drug faces FDA panel this week Jul 13, 2010 | not rated yet | 0
- FDA scrutinizes weight loss pill from Orexigen Dec 03, 2010 | not rated yet | 0
- FDA rejects highly-anticipated diet drug Qnexa Oct 29, 2010 | not rated yet | 0
- FDA to decide on Qnexa obesity drug in July Apr 10, 2012 | not rated yet | 0
- FDA panel recommends approval for Contrave Dec 08, 2010 | not rated yet | 0
- Motion perception revisited: High Phi effect challenges established motion perception assumptions Apr 23, 2013 | 3 / 5 (2) | 2
- Anything you can do I can do better: Neuromolecular foundations of the superiority illusion (Update) Apr 02, 2013 | 4.5 / 5 (11) | 5
- The visual system as economist: Neural resource allocation in visual adaptation Mar 30, 2013 | 5 / 5 (2) | 9
- Separate lives: Neuronal and organismal lifespans decoupled Mar 27, 2013 | 4.9 / 5 (8) | 0
- Sizing things up: The evolutionary neurobiology of scale invariance Feb 28, 2013 | 4.8 / 5 (10) | 14
How can there be villous adenoma in colon, if there are no villi there
9 hours ago As title suggest. Thanks :smile:
How can there be a term called "intestinal metaplasia" of stomach
May 21, 2013 Hello everyone, Ok Stomach's normal epithelium is simple columnar, now in intestinal type of adenocarcinoma of stomach it undergoes "intestinal...
Pressure-volume curve: Elastic Recoil Pressure don't make sense
May 18, 2013 From pressure-volume curve of the lung and chest wall (attached photo), I don't understand why would the elastic recoil pressure of the lung is...
If you became brain-dead, would you want them to pull the plug?
May 17, 2013 I'd want the rest of me to stay alive. Sure it's a lousy way to live but it beats being all-the-way dead. Maybe if I make it 20 years they'll...
MRI bill question
May 15, 2013 Dear PFers, The hospital gave us a $12k bill for one MRI (head with contrast). The people I talked to at the hospital tell me that they do not...
Ratio of Hydrogen of Oxygen in Dessicated Animal Protein
May 13, 2013 As an experiment, for the past few months I've been consuming at least one portion of Jell-O or unflavored Knox gelatin per day. I'm 64, in very...
- More from Physics Forums - Medical Sciences
More news stories
GlaxoSmithKline PLC says it's starting an unusual collaboration with the U.S. government to develop several antibiotics for both bioterrorism threats and bacterial infections resistant to current medicines.
Medications 40 minutes ago | not rated yet | 0
The new 13-valent pneumococcal conjugate vaccine (PCV13) appears to be as safe as the previous version used prior to 2010, the 7-valent pneumococcal conjugate vaccine (PCV7), according to a Kaiser Permanente study published ...
Medications 5 hours ago | not rated yet | 0
The University of Gothenburg Vaccine Research Institute (GUVAX) announces successful results in a placebo controlled phase I study of an oral, inactivated Escherichia coli diarrhea vaccine.
Medications 8 hours ago | not rated yet | 0
An experimental sleeping pill from US drug company Merck is effective at helping people fall and stay asleep, according to reviewers at the US Food and Drug Administration, which could soon approve the new drug.
Medications 22 hours ago | 4.2 / 5 (5) | 0
Transparent information on the evidence supporting global recommendations on paediatric medicines should be easily accessible in order to help policy makers decides on what drugs to include in their national drug lists, according ...
Medications 23 hours ago | not rated yet | 0
(HealthDay)—Migraines and depression can each cause a great deal of suffering, but new research indicates the combination of the two may be linked to something else entirely—a smaller brain.
24 minutes ago | not rated yet | 0 |
Until now, little was scientifically known about the human potential to cultivate compassion—the emotional state of caring for people who are suffering in a way that motivates altruistic behavior.
47 minutes ago | not rated yet | 0 |
A man who had contracted the coronavirus has died in Saudi Arabia, raising the death toll in the kingdom from the SARS-like virus to 17, the health ministry announced on its website on Wednesday.
42 minutes ago | not rated yet | 0
(HealthDay)—Over the last decade, the number of American children who die each year awaiting an organ donation dropped by more than half, new research reveals. And increasing numbers of children are receiving ...
33 minutes ago | not rated yet | 0
Canadian health authorities lifted Wednesday what was effectively a ban on gay men giving blood, announcing new rules making men who have not had sex with men in the past five years eligible.
27 minutes ago | not rated yet | 0